Previous 10 | Next 10 |
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing PR Newswire NEW YORK , Aug. 24, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech ...
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada Treatment with Strontium89 is available immediately in Canada via Named Patient Program PR Newswire NEW YORK , Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQ...
Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East Clionix will be the exclusive distributor of Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait, & Pakistan PR Newswire ...
Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company, Denis Corin, joined Stock Day host Everett Jolly. Jolly began the interview by asking abou...
Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience Company Expands Strontium89 Reach Through Partnership with WSI, a Federally Focused Contract Sales Organization PR Newswire NEW YORK , May 20, 2021 /PRNewswire/ -- Q BioMed Inc. ...
Q BioMed ([[QBIO]] +5.3%) signed a securities purchase agreement with privately-owned U.K.-based healthcare and technology aggregator Aedesius wherein latter has the opportunity to buy ~43% of the outstanding QBIO shares for $30M. The transaction is structured as an initial inv...
Q BioMed Insider to Invest up to $30M in the Company Aedesius Holdings Ltd. (AedesiusOne), a privately held global disruption aggregator, enters Into $30M Securities Purchase Agreement with Q BioMed Up front investment of up to $20M with an optional $10M in 6 month warrants ...
Q BioMed (QBIO) signed an agreement for Strontium89 to be included on the Federal Supply Schedule ((FSS)); final FSS contract is effective Mar.1 and has a five year term.The agreement provides U.S. veterans and other federal government agencies access to Strontium89 f...
Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs 5-year contract makes Strontium89 available to over 9 million VA beneficiaries PR Newswire NEW YORK , March 2, 2021 /PRNewswire/ -- Q BioMed Inc. ...
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US PR Newswire NEW YORK , Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage ...
News, Short Squeeze, Breakout and More Instantly...
Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...
Impac Mortgage Holdings, Inc. (IMPM) is expected to report for quarter end 2023-09-30 Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-09-30 Aldeyra Therapeutics Inc. (ALDX) is expected to report $-0.24 for Q3 2023 Zalando SE ADR (ZLNDY) is expected to report for...
thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...